Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Genzyme Therapeutics
4620 Kingsgate, Cascade Way, Oxford Business Park South, Oxford, Oxfordshire, OX4 2SU
Telephone: +44 (0)1865 405 200
Fax: +44 (0)1865 774 172
WWW: http://www.genzyme.co.uk
Medical Information Direct Line: +44 (0)1483 505 515
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com
Customer Care direct line: +44 (0)1865 405 200
Medical Information Fax: +44(0)1483 554 805

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 17/02/2012
PIL Fludara 50mg powder for solution for injection or infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/02/2012 and displayed until Current
Reasons for adding or updating:
  • Change to name of manufacturer
Updated on 13/04/2011 and displayed until 17/02/2012
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to information about pregnancy or lactation
Updated on 14/12/2009 and displayed until 13/04/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to Marketing Authorisation Holder
Updated on 02/03/2009 and displayed until 14/12/2009
Reasons for adding or updating:
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 16/05/2008 and displayed until 02/03/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change of licence holder
  • Change to Marketing Authorisation Holder
  • Change to MA holder contact details
Updated on 19/02/2008 and displayed until 16/05/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to warnings or special precautions for use
Updated on 19/02/2008 and displayed until 19/02/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to information about pregnancy or lactation
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
Updated on 18/09/2007 and displayed until 19/02/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 19/07/2007 and displayed until 18/09/2007
Reasons for adding or updating:
  • Change to name of manufacturer
Updated on 13/01/2006 and displayed until 19/07/2007
Reasons for adding or updating:
  • Change to storage instructions
  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to date of revision
  • Change to side-effects
Updated on 15/12/2004 and displayed until 13/01/2006
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 11/03/2003 and displayed until 15/12/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 19/07/2000 and displayed until 11/03/2003
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  fludarabine phosphate